Rolf Grempler
-
- Diabetes Treatment and Management 10
- Aging top 5%
- Surgery top 5%
- Pancreatic function and diabetes 10
- Molecular Biology top 10%
- Metabolism, Diabetes, and Cancer 8
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Kinase Regulation and GTPase Signaling 4
- Nephrology top 10%
-
- Chronic Lymphocytic Leukemia Research 4
-
- CAR-T cell therapy research 3
-
- Cancer Genomics and Diagnostics 3
Rolf Grempler
34 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Endocrinology, Diabetes and Metabolism 734
- Aging 51
- Surgery 585
- Molecular Biology 806
- Nephrology 55
Countries citing papers authored by Rolf Grempler
This map shows the geographic impact of Rolf Grempler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Grempler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Grempler more than expected).
Fields of papers citing papers by Rolf Grempler
This network shows the impact of papers produced by Rolf Grempler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Grempler. The network helps show where Rolf Grempler may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rolf Grempler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 31 | |
| 5 | 2021 | 24 | |
| 6 | 2018 | 14 | |
| 7 | 2016 | 33 | |
| 8 | 2014 | 55 | |
| 9 | 2012 | 65 | |
| 10 | 2012 | 11 | |
| 11 | 2011 | 42 | |
| 12 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsbreakdown → | 2011 | 494 |
| 13 | 2011 | 60 | |
| 14 | 2006 | 13 | |
| 15 | 2005 | 15 | |
| 16 | 2004 | 3 | |
| 17 | 2003 | 26 | |
| 18 | 2001 | 7 | |
| 19 | 2001 | 16 | |
| 20 | 2000 | 291 |
About Rolf Grempler
Rolf Grempler is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research, Genetics, Oncology and Biochemistry, having authored 35 papers that have together received 1.4k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (10 papers), Pancreatic function and diabetes (10 papers), Metabolism, Diabetes, and Cancer (8 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers), CAR-T cell therapy research (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (734 citations), Aging (51 citations), Surgery (585 citations), Molecular Biology (806 citations) and Nephrology (55 citations). Rolf Grempler has collaborated with scholars based in Germany, United States and Japan. Frequent co-authors include Michael Mark, Thomas Klein, Peter Eickelmann, Reinhard Walther, Dieter Schmoll, Frank Himmelsbach, Leo Thomas, Achim Sauer, Matthias Eckhardt and Dale E. Sharp. Their work appears in journals such as Biochemical Journal, Journal of Clinical Oncology, Cancer Research, Diabetes Obesity and Metabolism and FEBS Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.